This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lippman, S. M. Articles by Heymach, J. V. Search for Related Content PubMed PubMed Citation Articles by Lippman, S. M. Articles by Heymach, J. V.

The Convergent Development of Molecular-Targeted Drugs for Cancer Treatment and Prevention

Authors' Affiliations: Departments of ¹ Thoracic/Head and Neck Medical Oncology and ² Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Scott M. Lippman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Unit 432, 1515 Holcombe Boulevard. Houston, TX 77030-4009. Phone: 713-745-5439; Fax: 713-745-2012; E-mail: slippman{at}mdanderson.org.

Advances in our understanding of multistep and field carcinogenesis are erasing the clear demarcation of intraepithelial neoplasia from invasive neoplasia. The growing ability to define a very high risk of cancer is forging important commonalities between prevention and therapy, such as in potential prognostic/predictive markers, agents, and side effects that patients would be willing to tolerate, and the logistics of definitive trials. The emergence of promising new molecular-targeted agents and new technologies for screening and early detection provides new opportunities for applying clinical trial designs that integrate therapy and prevention end points. Such trials may be used to facilitate targeted drug development and help identify strategies for both cancer prevention and advanced cancer therapy. These several advances are creating a convergence of cancer therapy with cancer prevention that promises to streamline the development of targeted drugs and improve the control of major cancers.

This article has been cited by other articles:

				V. A. Papadimitrakopoulou, W. N. William Jr., A. J. Dannenberg, S. M. Lippman, J. J. Lee, F. G. Ondrey, D. E. Peterson, L. Feng, A. Atwell, A. K. El-Naggar, et al. Pilot Randomized Phase II Study of Celecoxib in Oral Premalignant Lesions Clin. Cancer Res., April 1, 2008; 14(7): 2095 - 2101. [Abstract] [Full Text] [PDF]

				A. Hoque, H. L. Parnes, M. E. Stefanek, J. V. Heymach, P. H. Brown, and S. M. Lippman Meeting Report: Fifth Annual AACR Frontiers in Cancer Prevention Research Cancer Res., October 1, 2007; 67(19): 8989 - 8993. [Abstract] [Full Text] [PDF]